Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II multicenter study of jaktinib hydrochloride tablets for steroid-refractory acute graft-versus-host disease
CTR20211758Phase 2Active
- Sponsor
- Zelgen
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of jaktinib in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Zelgen. Started Jul 2021; status: active.
02
Drugs
jaktinib
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on CTR20211758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211758.